Article Text

Download PDFPDF
American Society of Clinical Oncology 2013: Summary of Scientific Advancements in Gynecologic Cancer
  1. Ramez N. Eskander, MD and
  2. Krishnansu S. Tewari, MD
  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA.
  1. Address correspondence and reprint requests to Krishnansu S. Tewari, MD, University of California, Irvine, 101 The City Drive South, Bldg 56, Suite 264, Orange, CA, 92868. E-mail: ktewari{at}uci.edu

Abstract

Abstract The American Society of Clinical Oncology (ASCO) meeting was held in Chicago, Ill, from May 31, 2013, to June 4, 2013, and focused on “Building Bridges to Conquer Cancer.” An estimated 25,500 oncology professionals, with a broad range of interests, attended the meeting. Cervical cancer, a gynecologic malignancy with a significant global burden, was prominently featured at this year’s meeting. In a mark of exemplary scientific accomplishment within our specialty, 2 of the 5 general session plenaries investigated advancements in cervical cancer care, extending from improved screening to treatment of metastatic disease. This was followed by the presentation of several important phase 2 and 3 clinical trials in the Gynecologic Oncology Tract, focusing on cervical, ovarian, uterine, and breast cancer, which will be discussed in this report.

  • ASCO 2013
  • Cervical cancer
  • Bevacizumab
  • Breast cancer
  • Ovarian cancer
  • Uterine cancer

Statistics from Altmetric.com

Footnotes

  • This study was supported by an institutional National Institutes of Health T-32 training grant (Ruth L. Kirschstein NRSA Institutional Training Research Grant, 2T32 CA-060396-11).

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.